Skip to content

Study · Animal study (in vivo) · rat · 2020

3 results

Morphological Changes in the Large Intestine of Rats Subjected to Chronic Restraint Stress and Treated with Selank.

Mukhina AY, Mishina ES, Bobyntsev II, Medvedeva OA, Svishcheva MV, Kalutskii PV, Andreeva LA, Myasoedov NF

Bulletin of experimental biology and medicine1 Jun 2020Cited by 2 (Europe PMC)

PMID32651826 (opens in a new tab)DOI10.1007/s10517-020-04868-9 (opens in a new tab)PepBankPUB-32651826
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats under chronic restraint stress, Selank decreased corticosterone levels.

    In plain wordsIn rats under chronic restraint stress, Selank lowered the level of the stress hormone corticosterone.

    Peptide
    Selank
    Outcome
    DecreaseCorticosterone level
    Study

    ratn: not reported in source

    Chronic restraint stress in Wistar male rats
    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    80, 250 and 750 μg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    Selank administration led to a decrease in corticosterone levels
    2 context sentences
    Summary · context
    We studied the effects of Selank on the condition of the colon wall in Wistar male rats subjected to restraint stress.
    Summary · context
    Selank was injected intraperitoneally in doses of 80, 250, and 750 μg/kg 15 min before stress exposure.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats under chronic restraint stress, Selank reduced stress-induced pathomorphological changes in the colon wall.

    In plain wordsIn rats under chronic restraint stress, Selank reduced stress-related damage to the large intestine wall.

    Peptide
    Selank
    Outcome
    DecreasePathomorphological changes in the colon wall
    Study

    ratn: not reported in source

    Chronic restraint stress in Wistar male rats
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    80, 250 and 750 μg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    reduced pathomorphological manifestations of stress exposure, and accelerated adaptation.
    3 context sentences
    Summary · context
    In rats subjected to stress, signs of atrophy, inflammatory reaction, and changes in the number and functional activity of mast cells were observed against the background of increased corticosterone level.
    Summary · context
    We studied the effects of Selank on the condition of the colon wall in Wistar male rats subjected to restraint stress.
    Summary · context
    Selank was injected intraperitoneally in doses of 80, 250, and 750 μg/kg 15 min before stress exposure.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats under chronic restraint stress, Selank accelerated adaptation to stress.

    In plain wordsIn rats under chronic restraint stress, Selank sped up adaptation to the stress.

    Peptide
    Selank
    Outcome
    IncreaseAdaptation to stress
    Study

    ratn: not reported in source

    Chronic restraint stress in Wistar male rats
    Outcome group
    Stress hormones · Whole body
    Studied dose
    80, 250 and 750 μg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    accelerated adaptation.
    2 context sentences
    Summary · context
    We studied the effects of Selank on the condition of the colon wall in Wistar male rats subjected to restraint stress.
    Summary · context
    Selank was injected intraperitoneally in doses of 80, 250, and 750 μg/kg 15 min before stress exposure.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.